metallodrugs

Term used to define a pharmaceutical, having a activity center containing a metal. Platinum (cisplatin, carboplatin) and gold (Auranofin) compounds are well-known in cancer therapy whereas some other gold compounds (aurithiomalate, aurothioglucose) are important antiarthritic drugs. A wide range of Tc compounds (e.g. Tc-labelled antibodies, Tc-mercaptoacetyl glycine complex) are used for diagnostic imaging of renal, cardiac and cerebral functions and of various forms of cancer. Gadolinium (III) polyaminopolycarboxylic crown complexes are widely used as contrast agents in magnetic resonance imaging.



The term "metallodrugs" was found in the following pages:

Link database: Australia: University of Western Sydney: Biologically Active Drugs by Design Group
Themed Issue "Metallomics 2011" now available | EVISA's News
Chemical speciation analysis for the life sciences | EVISA's News
Toxicity of organomercury compounds | EVISA's News
EMA Issues Final Opinion Limiting Gadolinium Contrast Agents in Body Scans | EVISA's News
Chemical speciation analysis for life science | EVISA's News
Side effects of cisplatin chemotherpy: Platinum speciation matters | EVISA's News
European Medicines Agency recomments to pull linear Gadolinium-based MRI contrast agents from market | EVISA's News
Directory of scientists: Katarzyna Pawlak
Link database: Australia: University of Sydney: Group of Peter A. Lay
Speciation analysis of Gadolinium-based contrast agents using hydrophilic interaction liquid chromatography hyphenated with inductively coupled plasma-mass spectrometry by avoiding organic solvents | EVISA's News
Combined speciation analysis and elemental bioimaging provides new information about the retention of gadolinium in kidney following the application of some MRI contrast agents | EVISA's News
New Studies Question Safety of MRI Contrast Agents | EVISA's News
Copper molecule shows promise in fighting against cancer | EVISA's News
Directory of scientists: María Montes-Bayón
FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs | EVISA's News
All about Pharmacy and Pharmaceutical Sciences | EVISA's News
Identification and quantification of potential metabolites of Gd-based contrast agents | EVISA's News
What's new ? | EVISA's News
New Strategy for Speciation Analysis of Gadolinium retained in Bone after Application of MR Contrast Agents | EVISA's News